. Author manuscript; available in PMC: 2020 Sep 1.

Published in final edited form as: Patient Educ Couns. 2019 Apr 9;102(9):1636–1643. doi: 10.1016/j.pec.2019.04.012

Table 4.

Concordance between Clinician Chemotherapy-Induced Peripheral Neuropathy (CIPN) Discussion and Documentation Frequency (N = 159)

	CIPN Documentation [Yes]	CIPN Documentation [No]	Total
CIPN Discussion (N= 159)
No Discussion of Neuropathy	26 (29%)	63 (71%)	89
Discussion of Neuropathy	47 (67%)	23 (33%)	70
CIPN Discussion Initiation (n = 70)
Participant or Caregiver Initiated CIPN Discussion	19 (73%)	7 (27%)	26
Clinician Initiated CIPN Discussion	28 (64%)	16 (36%)	44
Other Severe Cancer Treatment- Related Symptoms (N = 159)
Participant Reported Other Severe Cancer Treatment-Related Symptoms	16 (37%)	27 (63%)	43
Participant Did Not Report Other Severe Cancer Treatment-Related Symptoms	57 (49%)	59(51%)	116
CIPN Symptom Report (n = 70)
Participant Reported CIPN Symptoms in Audio Recording	32 (73%)	12 (27%)	44
Participant Denied CIPN Symptoms in Audio Recording	15 (58%)	11 (42%)	26